ATE419267T1 - Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten - Google Patents

Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten

Info

Publication number
ATE419267T1
ATE419267T1 AT04761607T AT04761607T ATE419267T1 AT E419267 T1 ATE419267 T1 AT E419267T1 AT 04761607 T AT04761607 T AT 04761607T AT 04761607 T AT04761607 T AT 04761607T AT E419267 T1 ATE419267 T1 AT E419267T1
Authority
AT
Austria
Prior art keywords
surrogates
peptide binding
containing peptide
macrocycles containing
spacially
Prior art date
Application number
AT04761607T
Other languages
English (en)
Inventor
Pierre Deslongchamps
Yves Dory
Luc Ouellet
Gerald Villeneuve
Mahesh Ramaseshan
Daniel Fortin
Mark Peterson
Hamid Hoveyda
Sylvie Beaubien
Eric Marsault
Original Assignee
Tranzyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tranzyme Pharma Inc filed Critical Tranzyme Pharma Inc
Application granted granted Critical
Publication of ATE419267T1 publication Critical patent/ATE419267T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04761607T 2003-07-31 2004-08-02 Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten ATE419267T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49125003P 2003-07-31 2003-07-31
US49125303P 2003-07-31 2003-07-31
US49124903P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
ATE419267T1 true ATE419267T1 (de) 2009-01-15

Family

ID=34119808

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04761607T ATE419267T1 (de) 2003-07-31 2004-08-02 Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten

Country Status (7)

Country Link
US (2) US7550431B2 (de)
EP (1) EP1648923B1 (de)
JP (1) JP4928263B2 (de)
AT (1) ATE419267T1 (de)
CA (1) CA2533820C (de)
DE (1) DE602004018782D1 (de)
WO (1) WO2005012332A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3132403B2 (ja) 1996-11-28 2001-02-05 松下電工株式会社 粒状半導体封止材料の製造方法
DK1633774T3 (da) 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
AU2004261329B2 (en) * 2003-07-31 2011-10-27 Ocera Therapeutics, Inc. Spatially-defined macrocyclic compounds useful for drug discovery
WO2006046977A1 (en) * 2004-10-26 2006-05-04 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and methods of using the same
CA2583345A1 (en) * 2005-06-13 2006-12-28 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US8088733B2 (en) * 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
EP2431380A3 (de) 2006-09-11 2013-07-03 Tranzyme Pharma, Inc. Makrozyklischer Antagonist des Motilinrezeptors zur Behandlung von Magen-Darm-Motilitätsstörungen
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
GB0710863D0 (en) * 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
WO2010009334A1 (en) 2008-07-17 2010-01-21 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
US8338565B2 (en) * 2008-08-20 2012-12-25 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
KR101575703B1 (ko) 2009-02-27 2015-12-10 라퀄리아 파마 인코포레이티드 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체
EP2493910A1 (de) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Makrozyklische ghrelin-rezeptorantagonisten und gegenagonisten sowie verwendungsverfahren dafür
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2016144665A1 (en) 2015-03-06 2016-09-15 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
AU2016230008B2 (en) 2015-03-06 2020-08-27 Colorado State University Research Foundation Synthesis and utility of new capgroup largazole analogs
CA2998885C (en) 2015-09-24 2020-09-01 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
AU2016347456B2 (en) 2015-10-27 2018-12-13 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CA3024071C (en) * 2016-05-16 2023-02-21 Cyclenium Pharma Inc. Libraries of diverse macrocyclic compounds and methods of making and using the same
WO2017222935A1 (en) * 2016-06-20 2017-12-28 Kansas State University Research Foundation Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses
EP3388444A1 (de) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Antibakterielle peptidmakrozyklen und verwendung davon
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
CA3205814A1 (en) 2020-12-21 2022-06-30 Colorado State University Research Foundation Synthesis of structural analogs of largazole and associated compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
WO1996022304A1 (en) * 1995-01-20 1996-07-25 Molecumetics, Ltd. Conformationally constrained reverse-turn library and methods relating thereto
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5712253A (en) * 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
WO1998046631A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
US20020068301A1 (en) 1997-05-28 2002-06-06 Hung-Sen Lai Cyclic peptide libraries and methods of use thereof to identify binding motifs
US6165985A (en) * 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
EP1222197A4 (de) 1999-10-04 2004-07-21 Merck & Co Inc Mray gen und das enzym der pseudomonas aeruginosa
CA2284459C (en) * 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
CN1443198A (zh) * 2000-07-24 2003-09-17 阿达纳生物科学有限公司 Ghrelin拮抗剂
EP1312612A4 (de) 2000-08-24 2004-09-22 Chugai Pharmaceutical Co Ltd Zyklisches peptid-derivat
IL141276A0 (en) 2001-02-05 2002-03-10 Peptor Ltd Backbone cyclized radiolabelled somatostatin analogs
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
DK1633774T3 (da) * 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
AU2004261329B2 (en) * 2003-07-31 2011-10-27 Ocera Therapeutics, Inc. Spatially-defined macrocyclic compounds useful for drug discovery
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same

Also Published As

Publication number Publication date
WO2005012332A1 (en) 2005-02-10
EP1648923A4 (de) 2006-08-23
CA2533820A1 (en) 2005-02-10
EP1648923B1 (de) 2008-12-31
US8557765B2 (en) 2013-10-15
EP1648923A1 (de) 2006-04-26
US20050119169A1 (en) 2005-06-02
US20090312540A1 (en) 2009-12-17
CA2533820C (en) 2016-12-13
JP4928263B2 (ja) 2012-05-09
JP2007526895A (ja) 2007-09-20
US7550431B2 (en) 2009-06-23
DE602004018782D1 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
ATE419267T1 (de) Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten
CY1111901T1 (el) Χωροταξικα - προσδιορισμενες μακροκυκλικες ενωσεις χρησιμες για την ανακαλυψη φαρμακων
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
SG145725A1 (en) Anti-vegf antibodies
MX336807B (es) Composiciones y metodos para producir una composicion.
WO2006073941A3 (en) Polypeptides that bind br3 and uses thereof
GB0700909D0 (en) Novel antigen-binding polypeptides and their uses
EP1617802A4 (de) Cngh0010 spezifische polynucleotide, polypeptide, antikörper, zusammensetzungen, verfahren und verwendungen.
MXPA05011409A (es) Composiciones y metodos para la terapia de enfermedad inflamatoria intestinal.
TW200604149A (en) Norbornane based cycloaliphatic compounds containing nitrile groups
WO2008036337A3 (en) Predicted phosphorylation sites
WO2004037997A3 (en) Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
GB0312642D0 (en) Pharmaceutical composition
MX2007011411A (es) Interaccion rage/diaphanous y composiciones relacionadas y metodos.
AU2003264681A8 (en) Serological diagnostic method
TW200718711A (en) Polypeptides that bind BR3 and uses thereof
ATE430206T1 (de) Mss4 als antifungisches zielmolekül
WO2006008266A3 (en) Factor xi-binding proteins
ATE388239T1 (de) Cgt1 als antifungales target
WO2004047759A3 (en) Composition for treating chlamydia infections and method for identifying same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties